Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.49 |
| ▸ | CDC7 | O00311 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132126 | 0.84 | TSHR (0.48) | SPRALDH1A1HTTLMNAMAPT | |
| SCHEMBL26521585 | 0.84 | TSHR (0.48) | SPRALDH1A1HTTLMNAMAPT | |
| SCHEMBL30132060 | 0.81 | KMT2A (0.60) | ALDH1A1KDM4EHTTRXFP1ALPL | |
| SCHEMBL23723685 | 0.80 | PDE5A (0.41) | ALDH1A1KDM4EHTTRXFP1ALPL | |
| SCHEMBL26097137 | 0.78 | KMT2A (0.47) | ALDH1A1KDM4EALPLALPIKMT2A | |
| SCHEMBL26096345 | 0.78 | KMT2A (0.47) | ALDH1A1KDM4EALPLALPIKMT2A | |
| SCHEMBL30368718 | 0.78 | CDC7 (0.47) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL30132075 | 0.77 | ALPL (0.41) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL23723556 | 0.77 | ALPL (0.41) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL23723612 | 0.74 | PIM1 (0.43) | CDC7CCNE1CDK2ROCK1DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| EP-4100015-A1 | COMBINATION THERAPY FOR TREATING MPS1 | Gain Therapeutics SA (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115397423-A | Combination therapy for the treatment of MPS1 | 增益治疗股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| WO-2021156774-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | SPR 2645/4885CDC7 4673/4885CCNE1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.